Advertisement

European Archives of Oto-Rhino-Laryngology

, Volume 268, Issue 1, pp 123–129 | Cite as

Treatment of lymphatic malformations of head and neck with OK-432 sclerotherapy induce systemic inflammatory response

  • Mervi Närkiö-MäkeläEmail author
  • Teppo Mäkelä
  • Pia Saarinen
  • Päivi Salminen
  • Ilkka Julkunen
  • Anne Pitkäranta
Head and Neck

Abstract

Systemic immune responses after OK-432 (Picibanil) sclerotherapy in patients with head and neck lymphatic malformations (LM) were examined to achieve a better understanding of the mechanism of OK-432 sclerotherapy and to evaluate the long-term treatment outcome. Serum samples from 17 consecutive patients with head and neck LMs were collected during a total of 26 OK-432 treatment episodes. Serum C-reactive protein (CRP), interleukins (IL) 1β, 6, 8, 10, tumor necrosis factor (TNF)-α, interferon (IFN)-γ, RANTES, immune protein (IP)-10 and macrophage chemoattractant protein (MCP)-1 as well as blood leukocyte counts were determined. Clinical outcome of the treatment was evaluated at the last visit and from patient files. Elevated serum levels of IP-10 (means at baseline 702 ng/L, after 1 day 1180 ng/L, after 4 weeks 691 ng/L) were seen on day one after OK-432 sclerotherapy (p < 0.05). C-reactive protein and leukocyte counts 1 day after treatment differed statistically significantly (p < 0.05) from the baseline. No significant differences with other cytokines investigated were observed. Patients with macrocystic LM responded better than patients with microcystic LM (p = 0.01). The elevated levels of IP-10, C-reactive protein and leukocyte levels indicate that OK-432 sclerotherapy induces systemic immune responses in patients with LM. The mechanisms of OK-432 sclerotherapy are still not precisely understood, but the IP-10 elevation may reflect local antiangiogenetic properties of immunoactivation induced by OK-432.

Keywords

OK-432 IP-10 Systemic inflammatory response Lymphatic malformation 

Notes

Acknowledgments

We thank Kimmo Lappalainen, MD, for his kind help in processing the MRI scans.

Conflict of interest statement

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Hamoir M, Plouin-Gaudon I, Rombaux P, Francois G, Cornu AS, Desuter G, Clapuyt P, Debauche C, Verellen G, Beguin C (2001) Lymphatic malformations of the head and neck: a retrospective review and a support for staging. Head Neck 4:326–337CrossRefGoogle Scholar
  2. 2.
    Marler JJ, Mulliken JB (2001) Vascular anomalies: classification, diagnosis, and natural history. Facial Plast Surg Clin North Am 4:495–504Google Scholar
  3. 3.
    Banieghbal B, Davies MR (2003) Guidelines for the successful treatment of lymphangioma with OK-432. Eur J Pediatr Surg 2:103–107Google Scholar
  4. 4.
    Giguere CM, Bauman NM, Sato Y, Burke DK, Greinwald JH, Pransky S, Kelley P, Georgeson K, Smith RJ (2002) Treatment of lymphangiomas with OK-432 (Picibanil) sclerotherapy: a prospective multi-institutional trial. Arch Otolaryngol Head Neck Surg 10:1137–1144Google Scholar
  5. 5.
    Orvidas LJ, Kasperbauer JL (2000) Pediatric lymphangiomas of the head and neck. Ann Otol Rhinol Laryngol 4:411–421Google Scholar
  6. 6.
    Burrows PE, Mitri RK, Alomari A, Padua HM, Lord DJ, Sylvia MB, Fishman SJ, Mulliken JB (2008) Percutaneous sclerotherapy of lymphatic malformations with doxycycline. Lymphat Res Biol 3–4:209–216CrossRefGoogle Scholar
  7. 7.
    Rautio R, Keski-Nisula L, Laranne J, Laasonen E (2003) Treatment of lymphangiomas with OK-432 (Picibanil). Cardiovasc Intervent Radiol 1:31–36Google Scholar
  8. 8.
    Smith MC, Zimmerman MB, Burke DK, Bauman NM, Sato Y, Smith RJ, OK-432 Collaborative Study Group (2009) Efficacy and safety of OK-432 immunotherapy of lymphatic malformations. Laryngoscope 1:107–115Google Scholar
  9. 9.
    Hall N, Ade-Ajayi N, Brewis C, Roebuck DJ, Kiely EM, Drake DP, Spitz L, Pierro A (2003) Is intralesional injection of OK-432 effective in the treatment of lymphangioma in children? Surgery 3:238–242CrossRefGoogle Scholar
  10. 10.
    Ogita S, Tsuto T, Tokiwa K, Takahashi T (1987) Treatment of cystic hygroma in children with special reference to OK-432 therapy. Z Kinderchir 5:279–281Google Scholar
  11. 11.
    Fujino A, Moriya Y, Morikawa Y, Hoshino K, Watanabe T, Shimojima N, Kitajima M (2003) A role of cytokines in OK-432 injection therapy for cystic lymphangioma: an approach to the mechanism. J Pediatr Surg 12:1806–1809CrossRefGoogle Scholar
  12. 12.
    Ogita S, Tsuto T, Nakamura K, Deguchi E, Tokiwa K, Iwai N (1996) OK-432 therapy for lymphangioma in children: why and how does it work? J Pediatr Surg 4:477–480CrossRefGoogle Scholar
  13. 13.
    Wiegand S, Eivazi B, Sel S, Renz H, Werner JA, Folz BJ (2008) Analysis of cytokine levels in human lymphangiomas. In Vivo 22:253–256PubMedGoogle Scholar
  14. 14.
    Abbas AK, Lichtman AH (2005) Cytokines. In: Anonymous cellular and molecular immunology, 5th edn. Elsevier, Saunders, p 243Google Scholar
  15. 15.
    Miettinen M, Vuopio-Varkila J, Varkila K (1996) Production of human tumor necrosis factor alpha, interleukin-6, and interleukin-10 is induced by lactic acid bacteria. Infect Immun 12:5403–5405Google Scholar
  16. 16.
    Veckman V, Miettinen M, Matikainen S, Lande R, Giacomini E, Coccia EM, Julkunen I (2003) Lactobacilli and streptococci induce inflammatory chemokine production in human macrophages that stimulates Th1 cell chemotaxis. J Leukoc Biol 3:395–402CrossRefGoogle Scholar
  17. 17.
    Feldman ED, Weinreich DM, Carroll NM, Burness ML, Feldman AL, Turner E, Xu H, Alexander HR Jr (2006) Interferon gamma-inducible protein 10 selectively inhibits proliferation and induces apoptosis in endothelial cells. Ann Surg Oncol 1:125–133CrossRefGoogle Scholar
  18. 18.
    Saito M, Ebina T, Koi M, Yamaguchi T, Kawade Y, Ishida N (1982) Induction of interferon-gamma in mouse spleen cells by OK-432, a preparation of Streptococcus pyogenes. Cell Immunol 1:187–192CrossRefGoogle Scholar
  19. 19.
    Smith MC, Zimmerman MB, Burke DK, Bauman NM, Sato Y, Smith RJ, the OK-432 Collaborative Study Group*OK-432 Collaborative Study Group (2008) Efficacy and safety of OK-432 immunotherapy of lymphatic malformations. Laryngoscope 1:107–115Google Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Mervi Närkiö-Mäkelä
    • 1
    Email author
  • Teppo Mäkelä
    • 2
  • Pia Saarinen
    • 3
  • Päivi Salminen
    • 4
  • Ilkka Julkunen
    • 5
  • Anne Pitkäranta
    • 6
  1. 1.Department of OtorhinolaryngologyKuopio University Hospital and University of KuopioKuopioFinland
  2. 2.Department of Diagnostic RadiologyKuopio University HospitalKuopioFinland
  3. 3.Department of Plastic SurgeryHelsinki University Central HospitalHelsinkiFinland
  4. 4.Department of Pediatric SurgeryHelsinki University Central HospitalHelsinkiFinland
  5. 5.The National Institute for Health and Welfare (THL)HelsinkiFinland
  6. 6.Department of OtorhinolaryngologyHelsinki University Central Hospital and University of HelsinkiHelsinkiFinland

Personalised recommendations